Celcuity Inc. (CELC): Likely Leader in Next Generation of Breast Cancer Treatments

We just covered the Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential and Celcuity Inc. (NASDAQ:CELC) ranks 3rd on this list.

Celcuity Inc. (NASDAQ:CELC) stock went on a wild surge last year and hedge funds are continuing to buy the shares as they view the firm as a likely leader in the next generation of breast cancer treatments. A prominent catalyst for the company has been the stellar clinical results for gedatolisib, Celcuity’s lead candidate for HR+/HER2- advanced breast cancer. In March, results published in the Journal of Clinical Oncology confirmed that the gedatolisib triplet reduced the risk of disease progression or death by 76% compared to standard fulvestrant. The median progression-free survival (PFS) was 9.3 months for the triplet versus only 2.0 months for the control group. Funds view this 7.3-month incremental improvement as a best-in-class result that will likely disrupt the current standard of care.

There has been institutional positioning in Celcuity Inc. (NASDAQ:CELC) ahead of a major regulatory decision scheduled for this summer. In March, the firm announced that the FDA granted Priority Review for its New Drug Application for gedatolisib. The FDA has assigned a PDUFA goal date of July 2026. Institutional investors typically pile into de-risked biotech stocks three to four months before a PDUFA date, betting on a successful commercial launch. Celcuity is turning from a research lab into a commercial entity. It recently expanded its commercial headcount and added $30 million in debt financing.

While we acknowledge the risk and potential of CELC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than CELC and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXTIsrael Englander Stock Portfolio: Top 10 Stock Picks and Billionaire Stan Druckenmiller’s 10 Small and Mid-Cap Stock Picks with Huge Upside Potential.

Disclosure: None. Follow Insider Monkey on Google News.